You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Last Updated: February 16, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Cediranib

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Cediranib?

Cediranib is an investigational drug.

There have been 99 clinical trials for Cediranib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2006.

The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), AstraZeneca, and NCIC Clinical Trials Group.

Recent Clinical Trials for Cediranib
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal MelanomaMFARPhase 2
Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal MelanomaGrupo EspaƱol Multidisciplinar de MelanomaPhase 2
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast CancerNational Cancer Institute (NCI)Phase 2

See all Cediranib clinical trials

Clinical Trial Summary for Cediranib

Top disease conditions for Cediranib
Top clinical trial sponsors for Cediranib

See all Cediranib clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.